Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: An ACTTION systematic review
Authors:
- Shannon M. SmithSSShannon M. Smith
- Daniel R. ChangDCDaniel R. Chang
- Anthony PereiraAPAnthony Pereira
- Nirupa ShahNSNirupa Shah
- Ian GilronIGIan Gilron
- Nathaniel P. KatzNKNathaniel P. Katz
- Allison H. LinALAllison H. Lin
- Michael P. McDermottMMMichael P. McDermott
- Bob A. RappaportBRBob A. Rappaport
- Michael C. RowbothamMRMichael C. Rowbotham
- Cristina SampaioCSCristina Sampaio
- Dennis C. TurkDTDennis C. Turk
- 1 December 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 153 (12) , 2415-2421
Abstract
Recommendations for harms (ie, adverse events) reporting in randomized clinical trial publications were presented in a 2004 extension of the Consolidated Standards of Reporting Trials (CONSORT) statement. Our objectives were to assess harms reporting in 3 major pain journals (European Journal of Pain, Journal of Pain, and PAIN®) to determine whether harms reporting improved following publication of the 2004 CONSORT recommendations, and to examine study factors associated with adequacy of harms reporting. A total of 101 randomized, double-blind, noninvasive pharmacologic trials were identified in the 2000-2003 (epoch 1) and 2008-2011 (epoch 2) issues of these journals. Out of 10 reporting recommendations, the mean number fulfilled was 6.08 (SD2.65). Although more harms recommendations were fulfilled in epoch 2 (m(2)=6.49, SD2.66) than in epoch 1 (m(1)=5.39, SD2.52; P=0.04), only the recommendation to report harms per arm was satisfied by >90% of trials in epoch 2, whereas <60% reported withdrawals due to harms. Several trial characteristics (study design, participant type, pain type, frequency of treatment administration, treatment administration method, sponsor, and number of randomized participants) were significantly associated with harms reporting. However, when trial characteristics and epoch were entered into a multiple regression analysis, only trials studying pain patients, those using oral treatments, and industry-sponsored trials were associated with better harms reporting. Despite some improvement in harms reporting, greater improvement is needed to provide informative, consistent reporting of adverse events and safety in analgesic clinical trials.Keywords
This publication has 32 references indexed in Scilit:
- A snapshot and scorecard for analgesic clinical trials for chronic pain: The RReACT databasePain, 2012
- Low quality of reporting adverse drug reactions in paediatric randomised controlled trialsArchives of Disease in Childhood, 2010
- Reporting of Harm in Randomized Controlled Trials Published in the Urological LiteratureJournal of Urology, 2010
- Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendationsPain, 2010
- The Missing Voice of Patients in Drug-Safety ReportingNew England Journal of Medicine, 2010
- Core outcome measures for chronic pain clinical trials: IMMPACT recommendationsPain, 2005
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklistControlled Clinical Trials, 2002
- Reporting of Adverse Effects in Clinical Trials Should Be ImprovedJournal of Pain and Symptom Management, 1999
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996